Prevalence and prognosis of low-volume, oligorecurrent, hormone-sensitive prostate cancer amenable to lesion ablative therapy
Uro-Oncology
Related content
Uro-Oncology
Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk
Prostate Cancer Prostatic Dis
Azad AA, Armstrong AJ, Alcaraz A, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alekseev B, Iguchi T, Shore ND, Gomez-Veiga F, Rosbrook B, Lee HJ, Haas GP, Stenzl A
doi: 10.1038/s41391-021-00436-y
Uro-Oncology
Indirect Comparisons of Efficacy between Combination Approaches in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Network Meta-analysis
Eur Urol.
Sathianathen NJ, Koschel S, Thangasamy IA, Teh J, Alghazo O, Butcher G, Howard H, Kapoor J, Lawrentschuk N, Siva S, Azad A, Tran B, Bolton D, Murphy DG
doi: 10.1016/j.eururo.2019.09.004.
Uro-Oncology
Prostate Radiotherapy for Metastatic Hormone-sensitive Prostate Cancer: A STOPCAP Systematic Review and Meta-analysis
Eur Urol.
Burdett S, Boevé LM, Ingleby FC, Fisher DJ, Rydzewska LH, Vale CL, van Andel G, Clarke NW, Hulshof MC, James ND, Parker CC, Parmar MK, Sweeney CJ, Sydes MR, Tombal B, Verhagen PC, Tierney JF, STOPCAP M1 Radiotherapy Collaborators
doi: 10.1016/j.eururo.2019.02.003.
COMMENTED
Uro-Oncology
New Anti-Androgen Compounds Compared to Docetaxel in Metastatic Hormone Sensitive Prostate Cancer: Results from a Network Meta-Analysis
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
J Urol.
Marchioni M, Di Nicola M, Primiceri G, Novara G, Castellan P, Paul A, Veccia A, Autorino R, Cindolo L, Schips L
doi: 10.1097/JU.0000000000000636.
COMMENTED
Uro-Oncology
Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019
★ 2
Recommended and commented by
Prof. Dr Richard Cathomas, Faculty Member
doi: 10.1016/j.eururo.2020.01.012.
Uro-Oncology
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N Engl J Med.
James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, Ritchie AWS, Amos CL, Gilson C, Jones RJ, Matheson D, Millman R, Attard G, Chowdhury S, Cross WR, Gillessen S, Parker CC, Russell JM, Berthold DR, Brawley C, Adab F, Aung S, Birtle AJ, Bowen J, Brock S, Chakraborti P, Ferguson C, Gale J, Gray E, Hingorani M, Hoskin PJ, Lester JF, Malik ZI, McKinna F, McPhail N, Money-Kyrle J, O'Sullivan J, Parikh O, Protheroe A, Robinson A, Srihari NN, Thomas C, Wagstaff J, Wylie J, Zarkar A, Parmar MKB, Sydes MR, STAMPEDE Investigators
doi: 10.1056/NEJMoa1702900.
Uro-Oncology
Comparative Effectiveness of Radical Prostatectomy With Adjuvant Radiotherapy Versus Radiotherapy Plus Androgen Deprivation Therapy for Men With Advanced Prostate Cancer
Cancer.
Jang TL, Patel N, Faiena I, Radadia KD, Moore DF, Elsamra SE, Singer EA, Stein MN, Eastham JA, Scardino PT, Lin Y, Kim IY, Lu-Yao GL
doi: 10.1002/cncr.31726.
Uro-Oncology
Long-term outcomes of two ablation techniques for treatment of radio-recurrent prostate cancer
Prostate Cancer Prostatic Dis.
Nair SM, Peters M, Kurver P, Lavi A, Verhoeff JJC, van der Voort van Zyp JRN, van Son MJ, Chin JL
doi: 10.1038/s41391-020-00265-5.
Uro-Oncology
Hemi-Ablative Low-Dose-Rate Prostate Brachytherapy for Unilateral Localised Prostate Cancer
BJU Int.
Langley S, Uribe J, Uribe-Lewis S, Franklin A, Perna C, Horton A, Cunningham M, Higgins D, Deering C, Khaksar S, Laing R
doi: 10.1111/bju.14948.